

XAV-939

Catalog No: tcsc0494



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg

Size: 200mg



Specifications

CAS No:

284028-89-3

Formula:

$C_{14}H_{11}F_3N_2OS$

Pathway:

Epigenetics;Cell Cycle/DNA Damage;Stem Cell/Wnt

Target:

PARP;PARP; β -catenin

Purity / Grade:

>98%

Solubility:

DMSO : 21.5 mg/mL (68.84 mM; Need ultrasonic and warming)

Observed Molecular Weight:

312.31


Product Description

XAV-939 is a selective Wnt pathway **β-catenin**-mediated transcription inhibitor and axin stabilizing agent with **IC₅₀** values of 5 and 2 nM for the inhibition of TNKS1 and TNKS2, respectively.

IC50 & Target: IC50: 5 nM (TNKS1), 2 nM (TNKS2)^[6]

In Vitro: XAV939 (1 μM) strongly inhibits STF activity in SW480 cells, Wnt3a-stimulated STF activity in HEK293 cells, but does not affect CRE, NF-κB or TGF-β luciferase reporters. XAV939 regulates axin levels through tankyrase inhibition in HEK293 cell^[1]. XAV939 (0.5 μM, 1.0 μM) reduces DNA-PKcs protein levels 50% of the relative DMSO control in human lymphoblasts^[2]. XAV939 induces a second wave of pro-cardiomyocyte gene expression as shown by increased *Mesp1* and *IsI1* expression 2 to 4 days after Wnt inhibition, and by increased *Nkx2.5* expression 4 to 6 days after XAV939 addition^[3]. XAV-939 (10 nM) has a suppressive effect on elevated MMP-13 levels in both IL-1β-induced SW 1353 cells^[4].

In Vivo: XAV-939 (3 mL, 10 nM) has a suppressive effect on elevated MMP-13 levels in the rat OA model^[4]. XAV-939 (1 mg/mL, i.p.) ameliorates the psoriasiform skin disease induced by IMQ. XAV-939 results in a significant decrease in the IMQ-induced epidermal hyperplasia (indicated by acanthosis) and dermal inflammatory infiltrates in mice^[5].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!